吉西他滨联合奥沙利铂对多种化疗方案治疗失败后淋巴瘤患者的疗效及安全性评价
|
摘要
目的探讨多种化疗方案治疗失败后淋巴瘤患者采取吉西他滨联合奥沙利铂治疗的临床疗效与安全性。方法 66例经多种化疗方案治疗失败后的淋巴瘤患者,随机分为两组各33例。对照组采用吉西他滨治疗,观察组采用吉西他滨联合奥沙利铂治疗,比较两组的临床疗效、不良反应发生率以及6个月生存率。结果观察组的化疗总有效率和6个月生存率均显著高于对照组,差异有统计学意义(P <0.05)。两组化疗期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论对多种化疗方案治疗失败后的淋巴瘤患者采取吉西他滨联合奥沙利铂治疗临床疗效明显,安全性高。
Objective To explore the clinical efficacy and safety of gemcitabine combined with oxaliplatin in the treatment of lymphoma patients after failure of multiple chemotherapy regimens. Methods 66 patients with lymphoma after failure of multiple chemotherapy regimens were randomly divided into two groups, with 33 cases in each group. The control group was treated with gemcitabine,while the observation group was treated with gemcitabine combined with oxaliplatin. The clinical efficacy, incidence of adverse reactions and 6-month survival rate were compared between the two groups. Results The total effective rate of chemotherapy and 6-month survival rate of the observation group were significantly higher than those of the control group(P <0.05). No statistical difference was found between the two groups in the incidence of adverse reactions during chemotherapy(P >0.05). Conclusions Gemcitabine combined with oxaliplatin in the treatment of lymphoma patients after failure of multiple chemotherapy regimens has obvious clinical efficacy and high safety.
Objective To explore the clinical efficacy and safety of gemcitabine combined with oxaliplatin in the treatment of lymphoma patients after failure of multiple chemotherapy regimens. Methods 66 patients with lymphoma after failure of multiple chemotherapy regimens were randomly divided into two groups, with 33 cases in each group. The control group was treated with gemcitabine,while the observation group was treated with gemcitabine combined with oxaliplatin. The clinical efficacy, incidence of adverse reactions and 6-month survival rate were compared between the two groups. Results The total effective rate of chemotherapy and 6-month survival rate of the observation group were significantly higher than those of the control group(P <0.05). No statistical difference was found between the two groups in the incidence of adverse reactions during chemotherapy(P >0.05). Conclusions Gemcitabine combined with oxaliplatin in the treatment of lymphoma patients after failure of multiple chemotherapy regimens has obvious clinical efficacy and high safety.
引文
[1]闫世彬,陈忠光,马德亮,等.含吉西他滨的联合化疗方案治疗难治性非霍奇金淋巴瘤疗效[J].中国实验血液学杂志, 2017, 25(5):1415-1419.
[2]张新龙.吉西他滨联合奥沙利铂和地塞米松挽救治疗老年复发或难治性非霍奇金淋巴瘤的临床观察[J].实用老年医学, 2016, 30(12):1046-1047.
[3]施小梅,顾康生.吉西他滨联合奥沙利铂,地塞米松治疗非霍奇金淋巴瘤疗效观察[J].安徽医药, 2015, 19(7):1383-1386.
[4]李维玲.非霍奇金淋巴瘤鞘内化疗的研究进展[J].肿瘤预防与治疗, 2016, 29(3):176-180.
[5]万优萍.吉西他滨联合同步放化疗方案在晚期宫颈癌治疗中的应用价值[J].实用癌症杂志, 2016, 32(1):145-147.
[6]吴萍,敬小梅,余思思. GEMOX与GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效比较[J].医学临床研究, 2018, 35(6):1053-1055.
[7]魏雯,吴萍,李力,等. P-GEMOX方案与CHOP方案一线治疗结外NK/T淋巴瘤的疗效对比[J].肿瘤预防与治疗, 2016, 29(5):254-259.
[8]刘君,肖扬,郭建雄,等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究, 2016, 43(1):72-77.
[2]张新龙.吉西他滨联合奥沙利铂和地塞米松挽救治疗老年复发或难治性非霍奇金淋巴瘤的临床观察[J].实用老年医学, 2016, 30(12):1046-1047.
[3]施小梅,顾康生.吉西他滨联合奥沙利铂,地塞米松治疗非霍奇金淋巴瘤疗效观察[J].安徽医药, 2015, 19(7):1383-1386.
[4]李维玲.非霍奇金淋巴瘤鞘内化疗的研究进展[J].肿瘤预防与治疗, 2016, 29(3):176-180.
[5]万优萍.吉西他滨联合同步放化疗方案在晚期宫颈癌治疗中的应用价值[J].实用癌症杂志, 2016, 32(1):145-147.
[6]吴萍,敬小梅,余思思. GEMOX与GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效比较[J].医学临床研究, 2018, 35(6):1053-1055.
[7]魏雯,吴萍,李力,等. P-GEMOX方案与CHOP方案一线治疗结外NK/T淋巴瘤的疗效对比[J].肿瘤预防与治疗, 2016, 29(5):254-259.
[8]刘君,肖扬,郭建雄,等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究, 2016, 43(1):72-77.